|
EP2805972A1
|
|
Novel antibody useful in neurological or neurodegenerative disorders
|
|
EP2666786A1
|
|
Immunotherapy for intracranial hemorrhage
|
|
EP2579890A1
|
|
Treatment of coagulopathy with hyperfibrinolysis
|
|
CA2802072A1
|
|
Treatment of coagulopathy with hyperfibrinolysis
|
|
EP2289542A1
|
|
Treatment of neurological or neurodegenerative disorders
|
|
EP2289541A1
|
|
Treatment of neurological or neurodegenerative disorders
|
|
CN102481344A
|
|
Treatment of coagulopathy with hyperfibrinolysis
|
|
WO2010006634A1
|
|
Prevention and treatment of radiation injury
|
|
WO2010006635A1
|
|
Treatment of inflammatory bowel disease
|
|
WO2009007112A2
|
|
Thrombomodulin for increasing reperfusion and preventing blood vessels obstruction
|
|
EP2120049A1
|
|
Soluble thrombomodulin as a biomarker for treatments using anticoagulants
|
|
EP2050462A1
|
|
Improved treatment of stroke patients
|
|
WO2008022801A1
|
|
Method for the manufacture of a medicament for treating hemorrhagic stroke
|
|
US2008057050A1
|
|
Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
|
|
EP2014296A1
|
|
Novel strategies for increasing the reperfusion in obstructed blood vessel
|
|
EP1941879A1
|
|
Neuroprotective agent for the treatment of neuronal damage
|
|
EP1897554A1
|
|
Method for the manufacture of a medicament for treating hemorrhagic stroke
|
|
WO2007134617A1
|
|
Use of desmodus salivary plasminogen activator (dspa) for treating venous thromboembolism
|
|
US2006135425A1
|
|
Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
|
|
JP2006241109A
|
|
FUSION PROTEIN CONTAINING ANTIBODY AGAINST HUMAN P SELECTIN AND DSPAalpha1
|
